Depreciation & Amortization
The latest quarterly d&a is $611.97 Million with a quarter-over-quarter change of -41.89%. Depreciation and Amortization (D&A) is a non-cash expense that allocates the cost of tangible and intangible assets over their useful lives.
GSK D&A
Reported quarterly depreciation and amortization; no daily interpolation.
Current D&A
$611.97M
$611.97 Million
Quarter-over-Quarter Change
-41.89%
vs. $1.05B prior quarter
Historical Data
96
Quarters of data available
Quarterly D&A History
| Period | D&A | QoQ Change | % Change |
|---|---|---|---|
| Q1 2026 | $611.97M | $-441.17M | -41.89% |
| Q4 2025 | $1.05B | $-284.66M | -21.28% |
| Q3 2025 | $1.34B | $-253.65M | -15.94% |
| Q2 2025 | $1.59B | +$528.39M | +49.70% |
| Q1 2025 | $1.06B | +$547.60M | +106.23% |
| Q4 2024 | $515.47M | $-756.37M | -59.47% |
| Q3 2024 | $1.27B | +$464.03M | +57.44% |
| Q2 2024 | $807.81M | $-70.50M | -8.03% |
| Q1 2024 | $878.31M | $-981.12M | -52.76% |
| Q4 2023 | $1.86B | +$1.15B | +163.19% |
| Q3 2023 | $706.50M | +$132.77M | +23.14% |
| Q2 2023 | $573.72M | $-215.34M | -27.29% |
| Q1 2023 | $789.06M | +$779.14M | +7851.87% |
| Q4 2022 | $9.92M | $-1.74B | -99.43% |
| Q3 2022 | $1.75B | +$982.54M | +127.89% |
| Q2 2022 | $768.27M | +$219.28M | +39.94% |
| Q1 2022 | $548.99M | $-10.92M | -1.95% |
| Q4 2021 | $559.91M | $-1.13B | -66.81% |
| Q3 2021 | $1.69B | +$633.15M | +60.07% |
| Q2 2021 | $1.05B | +$556.62M | +111.92% |
| Q1 2021 | $497.36M | $-1.22B | -71.09% |
| Q4 2020 | $1.72B | +$892.63M | +107.85% |
| Q3 2020 | $827.63M | +$2.27B | +157.29% |
| Q2 2020 | $-1.44B | $-1.69B | -700.06% |
| Q1 2020 | $240.73M | +$423.58M | +231.65% |
| Q4 2019 | $-182.85M | $-813.14M | -129.01% |
| Q3 2019 | $630.29M | $-354.83M | -36.02% |
| Q2 2019 | $985.12M | $-556.85M | -36.11% |
| Q1 2019 | $1.54B | +$666.79M | +76.19% |
| Q4 2018 | $875.18M | +$228.94M | +35.43% |
| Q3 2018 | $646.24M | +$388.78M | +151.00% |
| Q2 2018 | $257.46M | $-412.99M | -61.60% |
| Q1 2018 | $670.45M | +$906.76M | +383.71% |
| Q4 2017 | $-236.31M | $-1.15B | -125.79% |
| Q3 2017 | $916.22M | $-499.74M | -35.29% |
| Q2 2017 | $1.42B | +$1.01B | +246.19% |
| Q1 2017 | $409.01M | $-360.38M | -46.84% |
| Q4 2016 | $769.39M | +$521.62M | +210.53% |
| Q3 2016 | $247.76M | $-285.88M | -53.57% |
| Q2 2016 | $533.64M | $-267.57M | -33.40% |
| Q1 2016 | $801.22M | +$382.80M | +91.49% |
| Q4 2015 | $418.42M | +$64.46M | +18.21% |
| Q3 2015 | $353.96M | $-785.25M | -68.93% |
| Q2 2015 | $1.14B | +$565.89M | +98.70% |
| Q1 2015 | $573.32M | +$331.91M | +137.49% |
| Q4 2014 | $241.41M | $-376.26M | -60.92% |
| Q3 2014 | $617.67M | $-23.77M | -3.71% |
| Q2 2014 | $641.44M | $-313.18M | -32.81% |
| Q1 2014 | $954.62M | +$1.65B | +236.51% |
| Q4 2013 | $-699.31M | $-1.88B | -159.11% |
| Q3 2013 | $1.18B | +$352.72M | +42.48% |
| Q2 2013 | $830.38M | $-19.36M | -2.28% |
| Q1 2013 | $849.74M | $-114.64M | -11.89% |
| Q4 2012 | $964.38M | +$531.24M | +122.65% |
| Q3 2012 | $433.14M | +$45.47M | +11.73% |
| Q2 2012 | $387.67M | +$3.53M | +0.92% |
| Q1 2012 | $384.13M | $-6.06M | -1.55% |
| Q4 2011 | $390.19M | $-509.40M | -56.63% |
| Q3 2011 | $899.59M | +$153.19M | +20.52% |
| Q2 2011 | $746.40M | +$538.05M | +258.24% |
| Q1 2011 | $208.35M | $-80.16M | -27.78% |
| Q4 2010 | $288.52M | $-600.95M | -67.56% |
| Q3 2010 | $889.46M | +$198.93M | +28.81% |
| Q2 2010 | $690.53M | $-16.89M | -2.39% |
| Q1 2010 | $707.43M | +$199.88M | +39.38% |
| Q4 2009 | $507.55M | $-261.05M | -33.96% |
| Q3 2009 | $768.60M | +$498.71M | +184.78% |
| Q2 2009 | $269.89M | $-593.71M | -68.75% |
| Q1 2009 | $863.60M | +$517.50M | +149.52% |
| Q4 2008 | $346.10M | $-357.22M | -50.79% |
| Q3 2008 | $703.32M | +$129.57M | +22.58% |
| Q2 2008 | $573.74M | $-41.17M | -6.70% |
| Q1 2008 | $614.92M | +$410.35M | +200.59% |
| Q4 2007 | $204.57M | $-605.65M | -74.75% |
| Q3 2007 | $810.22M | +$308.17M | +61.38% |
| Q2 2007 | $502.05M | $-37.10M | -6.88% |
| Q1 2007 | $539.15M | +$400.05M | +287.61% |
| Q4 2006 | $139.10M | $-428.21M | -75.48% |
| Q3 2006 | $567.31M | $-83.54M | -12.84% |
| Q2 2006 | $650.85M | +$247.82M | +61.49% |
| Q1 2006 | $403.03M | $-754,017.52 | -0.19% |
| Q4 2005 | $403.78M | $-42.41M | -9.50% |
| Q3 2005 | $446.19M | $-35.70M | -7.41% |
| Q2 2005 | $481.89M | +$204.03M | +73.43% |
| Q1 2005 | $277.86M | +$368.90M | +405.21% |
| Q4 2004 | $-91.04M | $-668.97M | -115.75% |
| Q3 2004 | $577.93M | +$20.95M | +3.76% |
| Q2 2004 | $556.98M | $-20.82M | -3.60% |
| Q1 2004 | $577.80M | +$349.40M | +152.98% |
| Q4 2003 | $228.40M | $-414.68M | -64.48% |
| Q3 2003 | $643.08M | +$343.46M | +114.63% |
| Q2 2003 | $299.62M | +$41.88M | +16.25% |
| Q1 2003 | $257.74M | $-41.74M | -13.94% |
| Q4 2002 | $299.48M | $-61.37M | -17.01% |
| Q3 2002 | $360.85M | +$117.08M | +48.03% |
| Q2 2002 | $243.76M | — | — |
Related Metrics
About GSK plc
GSK plc, a global pharmaceutical entity founded in 1715 and headquartered in Brentford, United Kingdom, dedicates its efforts to the research, development, and manufacturing of a wide array of medical solutions. Until May 2022, the company was known as GlaxoSmithKline plc. Its primary objective is to prevent and treat illnesses by producing both vaccines and a comprehensive range of specialty and general medicines for markets across the United Kingdom, the United States, and internationally. The company's operations are organized into two key divisions: Commercial Operations and Total R&D. Its extensive vaccine portfolio includes immunizations against shingles, meningitis, respiratory syncytial virus (RSV), seasonal and pandemic influenza, and polio. Beyond preventative care, GSK provides diverse therapeutic products covering critical areas such as HIV, oncology, respiratory and immunology conditions, and other specialized medical fields. This also encompasses inhaled treatments for chronic respiratory ailments like asthma and chronic obstructive pulmonary disease (COPD), along with antibiotics for various infections. Innovation at GSK is frequently driven by strategic partnerships. Notable collaborations include an agreement with CureVac to advance mRNA-based influenza vaccines, and alliances with Wave Life Sciences and Elsie Biotechnologies focused on developing oligonucleotide platforms. Furthermore, GSK has established two distinct strategic collaborations with Relation to progress therapeutics for fibrotic diseases and osteoarthritis. The company is also engaged in a multi-target strategic alliance aimed at developing pioneering treatments for individuals suffering from Parkinson's disease, and a partnership with Flagship Pioneering to identify novel medicines and vaccines.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Luke Victor Miels